Ipamorelin works by activating ghrelin receptors, triggering short, controlled bursts of growth hormone that closely mimic the bodys natural rhythm
Retatrutide is an investigational triple agonist (GLP-1, GIP, and glucagon receptors) not yet licensed by the MHRA or EMA, with Phase 2 data suggesting significant weight reduction but Phase 3 confirmation still required
They are not intended for diagnosis, treatment, cure, or prevention of any disease, and must not be administered to humans or animals
This targeted, or regioselective, activation of IL-2 may help explain the broader improvements in neuroimmune integration and stress resilience observed in older biological systems
Others struggle to maintain weight loss without ongoing support